¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×Ü°æÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ 7GsKD=bl]  
sV  a0eGc  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© S \]O8#OX  
/"?DOsJ.  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© A5yVxSF  
d'ZNp2L  
1.Co-stimulators (or co-stimulating molecules) F/5G~17  
ylZQwICk  
2.NK-kB "UMaZgI  
n >y,{"J{  
3.Immunoglobulin superfamily b+|Jw\k  
MZ,1mR  
4.antigen-presenting cell (APC) y ;[~(Yg[  
tjx8 UgSi  
5.death domain k9rws  
JK =A=  
6.CCR and CXCR JFm@jc  
z.cDb kf}  
7.Lectin (or mitogen) NLMvi!5w,  
n]IF`kYQV  
8.Clusters of differentiation, CD) Z?'CS|u d  
4<#ItQ(  
9.B7 family b}R_@_<u  
1z6aMd6.  
10.Cytotoxic T lymphocyte, CTL) 7_1 Iadb  
Ea@0>_U|  
11.IL-15 and IL-15 receptor (IL-15R) _C/|<Ot:  
'\#q7YjaL  
12.MHC restriction YP02/*'  
#Zm`*s`  
13.Affinity-chromatography ; CCg]hX  
F6q=W#~  
14.Cyctosprin A, CsA ':4<[Vk  
lKejWT`;  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) utZI'5i  
V|'@D#\  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© lubsLI  
ElW\;C:K*  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 e`4mrBtz|  
1yE',9?  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ #'&-S@/nQs  
w PR Ns9^  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 F-3=eKZ  
5_!L"sJ  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© -KGJr  
~%*l>GkP*  
ÃâÒßѧרҵ£º "Q OQ  
K`N$nOw  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ "Y+VNS  
QgU]3`z"  
Ïû»¯ÄÚ¿Æ£º 4xW~@m eNB  
%.$!VTO"  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ (>0`e8v!  
z#Jw?K_  
ѪҺ²¡Ñ§×¨Òµ£º F[\T'{  
U[pHT _U  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛ̳ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»